<DOC>
	<DOCNO>NCT00169455</DOCNO>
	<brief_summary>Rotavirus ( RV ) important cause acute gastroenteritis ( GE ) require hospitalization infant young child develop develop country frequent cause death child less 5 year age . GSK Biologicals develop vaccine human rotavirus gastroenteritis . In study , immunogenicity , reactogenicity safety HRV vaccine evaluate store reconstituted circumstance different recommendation : i.e . reconstitute buffer store 7 day 37°C reconstitution . In addition , effect feeding explore HRV vaccine reconstitute without buffer .</brief_summary>
	<brief_title>Assess Immunogenicity Human Rotavirus ( HRV ) Vaccine After Reconstitution Without Buffering Agent ; &amp; Evaluate Immunogenicity , Reactogenicity &amp; Safety Vaccine After Storage 7 37°C Following 2 Doses Healthy Infants</brief_title>
	<detailed_description>Assess effect immunogenicity administration vaccine without buffer agent &amp; ass heat stability term immunogenicity , reactogenicity &amp; safety GSK Biologicals ' oral live attenuate human rotavirus ( HRV ) vaccine follow 0,2 schedule , healthy infant previously uninfected human rotavirus</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA : A male female , include , 6 12 week ( 4290 day ) age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . EXCLUSION CRITERIA : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine placebo , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug prior first vaccine dose , since birth . ( For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day . Inhaled topical steroid allow . ) Planned administration vaccine ( except routine paediatric vaccine ) foresee study protocol . ( If exceptionally OPV give , administer least 14 day apart HRV vaccine placebo dose . ) Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation GI tract serious medical condition determine investigator . History allergic disease reaction likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . Major congenital defect serious chronic illness . Gastroenteritis within 7 day precede study vaccine administration ( warrant deferral vaccination ) . Administration immunoglobulins and/or blood product since birth plan administration study period . Oral intake immunoglobulin via e.g . breastfeeding allow . Previous confirm occurrence RV gastroenteritis .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>